Growth hormone increase by luteinizing hormone-releasing hormone reflects gonadotroph-related characteristics in acromegaly.
Acromegaly
Gonadotropin
LHRH
Somatostatin
Steroidogenic factor 1
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
accepted:
27
05
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
We previously showed the clinical characteristics of acromegaly with a paradoxical growth hormone (GH) response to oral glucose or thyrotropin-releasing hormone. However, the clinical characteristics of acromegaly with an increased GH response to luteinizing hormone-releasing hormone (LHRH responders) remain unclear. The aim of the present study was to evaluate the clinical characteristics, especially gonadotroph-related characteristics of LHRH responders in acromegaly. The clinical characteristics of 33 LHRH responders and 81 LHRH nonresponders were compared. No differences in age, sex or basal serum levels of GH, insulin-like growth factor-1 (IGF-1), and gonadotropin were observed between the two groups. Steroidogenic factor 1 (SF-1), gonadotropin-releasing hormone receptor (GnRHR), and LH expression was more frequently observed in LHRH responders (P < 0.05). In addition, a greater increased rate of GH after LHRH loading, and the proportion of GnRHR and gonadotropin expression was observed in pituitary tumor with SF-1 expression than that without the expression (P < 0.01). LHRH responders showed a greater GH decrease in the octreotide test and a greater IGF-1 decrease after first-generation somatostatin ligand than LHRH nonresponders (P < 0.05). Furthermore, the proportion of hypointense pituitary tumors on T2-weighted magnetic resonance imaging and tumors with densely granulated type was higher in LHRH responders than in LHRH nonresponders, respectively (P < 0.05). No difference between the two groups was observed in either somatostatin receptor 2 or 5 expression. The increased GH response to LHRH is associated with the gonadotroph-related characteristics. This response may reflect the biological characteristics of somatotroph tumors.
Identifiants
pubmed: 38954291
doi: 10.1007/s11102-024-01410-2
pii: 10.1007/s11102-024-01410-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K17983
Organisme : Health Labour Sciences Research
ID : 23FC1042
Informations de copyright
© 2024. The Author(s).
Références
Mukai K, Otsuki M, Tamada D, Kitamura T, Hayashi R, Saiki A, Goto Y, Arita H, Oshino S, Morii E, Saitoh Y, Shimomura I (2019) Clinical characteristics of acromegalic patients with paradoxical growth hormone response to oral glucose load. J Clin Endocrinol Metab 104(5):1637–1644
doi: 10.1210/jc.2018-00975
pubmed: 30476255
Arita H, Kinoshita M, Oshino S, Kitamura T, Otsuki M, Kasayama S, Shimokawa T, Shimomura I, Yoshimine T, Saitoh Y (2012) Biological characteristics of growth hormone-producing pituitary adenomas are different according to responsiveness to thyrotropin-releasing hormone. J Clin Endocrinol Metab 97(8):2741–2747
doi: 10.1210/jc.2012-1125
pubmed: 22569237
Scaroni C, Albiger N, Daniele A, Dassie F, Romualdi C, Vazza G, Regazzo D, Ferraù F, Barresi V, Maffeis V, Gardiman MP, Cannavò S, Maffei P, Ceccato F, Losa M, Occhi G (2019) Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 104(3):856–862
doi: 10.1210/jc.2018-01360
pubmed: 30285115
Atquet V, Alexopoulou O, Maiter D (2021) Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load. Eur J Endocrinol 185(2):313–321
doi: 10.1530/EJE-21-0324
Watanobe H, Tamura T (1995) Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly. Neuropeptides 28(2):115–124
doi: 10.1016/0143-4179(95)90083-7
pubmed: 7746355
Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33(1):6–26
doi: 10.1007/s12022-022-09703-7
pubmed: 35291028
Lawrence AM, Goldfine ID, Kirsteins L (1970) Growth hormone dynamics in acromegaly. J Clin Endocrinol Metab 31(3):239–247
doi: 10.1210/jcem-31-3-239
pubmed: 4916537
Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, Teramoto A, Tatsumi K, Tachibana K, Katsumata N, Horikawa R (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59(9):771–780
doi: 10.1507/endocrj.EJ12-0110
pubmed: 22673406
Puig-Domingo M (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol 83:3–14
doi: 10.1111/cen.12731
Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Rahman MM, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82–91
doi: 10.1007/s12022-008-9029-z
pubmed: 18629656
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Grangé LM, Schillo F, Delemer B, Barlier A, Branger DF, Locard SB, Santos A, Chanson P, Raverot G (2022) Predictive factors of somatostatin receptor ligand response in acromegaly—a prospective study. J Clin Endocrinol Metab 107(11):2982–2991
doi: 10.1210/clinem/dgac512
pubmed: 36136828
Borota OC, Heck A, Schulz S, Nesland JM, Pettersen JR, Lekva T, Alafuzoff I, Bollerslev J (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98(11):1730–1739
doi: 10.1210/jc.2013-2145
Heck A, Ringstad G, Fougner SL, Borota OC, Nome T, Pettersen JR, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol 77:72–78
doi: 10.1111/j.1365-2265.2011.04286.x
Utsumi A, Hanew K, Sugawara A, Shimizu Y, Murakami O, Ikeda H, Yoshinaga K (1992) Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly—the effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone. J Endocrinol Investig 15:167–171
doi: 10.1007/BF03348697
Shibasaki T, Hotta M, Masuda A, Imaki T, Obara N, Hizuka N, Takano K, Wakabayashi I, Demura H, Ling N (1986) Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly. J Clin Endocrinol Metab 63(1):167–173
doi: 10.1210/jcem-63-1-167
pubmed: 2872226
Rymuza J, Kober P, Rusetska N, Mossakowska BJ, Maksymowicz M, Nyc A, Baluszek S, Zieliński G, Kunicki J, Bujko M (2022) Transcriptomic classification of pituitary neuroendocrine tumors causing acromegaly. Cells 11(23):3846
doi: 10.3390/cells11233846
pubmed: 36497102
pmcid: 9738119
Mete O, Alshaikh OM, Cintosun A, Ezzat S, Asa SL (2018) Synchronous multiple pituitary neuroendocrine tumors of different cell lineages. Endocr Pathol 29(4):332–338
doi: 10.1007/s12022-018-9545-4
pubmed: 30215160
Fookeerah P, Varikatt W, Shingde M, Dexter MAJ, McLean M (2023) Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1. Endocr Connect 12(11):e230328. https://doi.org/10.1530/EC-23-0328
doi: 10.1530/EC-23-0328
pubmed: 37851558
pmcid: 10563595
Dottermusch M, Ryba A, Ricklefs FL, Flitsch J, Schmid S, Glatzel M, Saeger W, Neumann JE, Schüller U (2024) Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features. Acta Neuropathol 147(1):16. https://doi.org/10.1007/s00401-024-02686-1
doi: 10.1007/s00401-024-02686-1
pubmed: 38228887
pmcid: 10791732
Rick J, Jahangiri A, Flanigan PM, Chandra A, Kunwar S, Blevins L, Aghi MK (2018) Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. J Neurosurg 131(1):147–153
doi: 10.3171/2018.4.JNS18230
pubmed: 30215558